| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Androgen | 26 | 2021 | 878 | 2.400 |
Why?
|
| Prostatic Neoplasms | 20 | 2016 | 5767 | 0.960 |
Why?
|
| Androgen Receptor Antagonists | 5 | 2016 | 112 | 0.910 |
Why?
|
| Testosterone | 6 | 2021 | 619 | 0.880 |
Why?
|
| Androgen-Insensitivity Syndrome | 3 | 2011 | 35 | 0.860 |
Why?
|
| Androgens | 10 | 2016 | 511 | 0.810 |
Why?
|
| Hypogonadism | 3 | 2021 | 257 | 0.780 |
Why?
|
| Caspases | 5 | 2001 | 661 | 0.620 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 7 | 2004 | 1493 | 0.610 |
Why?
|
| Apoptosis | 13 | 2009 | 7591 | 0.520 |
Why?
|
| Staurosporine | 4 | 2001 | 143 | 0.460 |
Why?
|
| Hydroxamic Acids | 1 | 2016 | 442 | 0.450 |
Why?
|
| Genetic Variation | 3 | 2016 | 2086 | 0.440 |
Why?
|
| Precision Medicine | 2 | 2011 | 1154 | 0.430 |
Why?
|
| Quinazolines | 1 | 2016 | 923 | 0.390 |
Why?
|
| Prostatic Hyperplasia | 3 | 2000 | 210 | 0.370 |
Why?
|
| High-Throughput Screening Assays | 2 | 2016 | 216 | 0.350 |
Why?
|
| Transcription, Genetic | 7 | 2016 | 3154 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 2403 | 0.350 |
Why?
|
| Cachexia | 3 | 2023 | 161 | 0.340 |
Why?
|
| Castration | 3 | 2012 | 122 | 0.330 |
Why?
|
| Anilides | 4 | 2008 | 268 | 0.330 |
Why?
|
| Androgen Antagonists | 5 | 2008 | 411 | 0.320 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 778 | 0.310 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 986 | 0.290 |
Why?
|
| Metribolone | 1 | 2006 | 48 | 0.290 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2012 | 1678 | 0.280 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2004 | 2488 | 0.270 |
Why?
|
| Cell Nucleus | 4 | 2009 | 1620 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2012 | 2054 | 0.260 |
Why?
|
| Enzyme Inhibitors | 9 | 2005 | 1879 | 0.260 |
Why?
|
| Mutation | 7 | 2011 | 15179 | 0.250 |
Why?
|
| HeLa Cells | 7 | 2011 | 1643 | 0.250 |
Why?
|
| Signal Transduction | 7 | 2016 | 11965 | 0.250 |
Why?
|
| Dihydrotestosterone | 6 | 2012 | 118 | 0.250 |
Why?
|
| Hyperthyroidism | 1 | 2004 | 52 | 0.240 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2005 | 342 | 0.240 |
Why?
|
| Persian Gulf Syndrome | 1 | 2023 | 14 | 0.230 |
Why?
|
| Zea mays | 1 | 2023 | 46 | 0.230 |
Why?
|
| Carrier Proteins | 4 | 2002 | 2022 | 0.220 |
Why?
|
| Genetic Therapy | 2 | 2002 | 1616 | 0.220 |
Why?
|
| Weight Loss | 4 | 2021 | 627 | 0.220 |
Why?
|
| Insulin-Like Growth Factor I | 6 | 2023 | 630 | 0.220 |
Why?
|
| Cerebral Palsy | 1 | 2023 | 63 | 0.220 |
Why?
|
| Orchiectomy | 1 | 2003 | 214 | 0.210 |
Why?
|
| Carcinoma, Medullary | 1 | 2004 | 248 | 0.210 |
Why?
|
| Male | 39 | 2023 | 123000 | 0.210 |
Why?
|
| bcl-2-Associated X Protein | 5 | 2004 | 367 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 9 | 2008 | 5395 | 0.200 |
Why?
|
| Lovastatin | 2 | 1998 | 58 | 0.190 |
Why?
|
| Caspase 7 | 5 | 2001 | 35 | 0.190 |
Why?
|
| Veterans | 2 | 2023 | 1641 | 0.180 |
Why?
|
| Cysteine Endopeptidases | 2 | 1999 | 251 | 0.180 |
Why?
|
| src-Family Kinases | 3 | 2016 | 478 | 0.180 |
Why?
|
| Humans | 52 | 2023 | 261506 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2016 | 4938 | 0.180 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2020 | 127 | 0.170 |
Why?
|
| Tosyl Compounds | 4 | 2008 | 40 | 0.170 |
Why?
|
| End Stage Liver Disease | 1 | 2021 | 170 | 0.170 |
Why?
|
| Pituitary Function Tests | 1 | 2018 | 8 | 0.170 |
Why?
|
| Remote Consultation | 1 | 2018 | 37 | 0.160 |
Why?
|
| Bone Diseases | 1 | 2019 | 143 | 0.160 |
Why?
|
| Hypopituitarism | 1 | 2018 | 33 | 0.160 |
Why?
|
| Adenoviridae | 2 | 2002 | 1459 | 0.160 |
Why?
|
| Tryptophan | 1 | 2018 | 127 | 0.160 |
Why?
|
| Behavior Therapy | 1 | 2021 | 298 | 0.160 |
Why?
|
| Human Growth Hormone | 1 | 2018 | 82 | 0.160 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 14289 | 0.160 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 1998 | 153 | 0.160 |
Why?
|
| Peptides | 2 | 2021 | 1479 | 0.150 |
Why?
|
| Reproduction | 1 | 2020 | 253 | 0.150 |
Why?
|
| Habenula | 1 | 2018 | 44 | 0.150 |
Why?
|
| Peptide Hormones | 3 | 2006 | 75 | 0.150 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 173 | 0.150 |
Why?
|
| Endocrinology | 1 | 2018 | 139 | 0.140 |
Why?
|
| Cell Survival | 4 | 2016 | 3045 | 0.140 |
Why?
|
| Prostate | 3 | 1998 | 1088 | 0.140 |
Why?
|
| Neural Pathways | 1 | 2018 | 298 | 0.140 |
Why?
|
| Estrogens | 1 | 2020 | 751 | 0.130 |
Why?
|
| Transfection | 6 | 2008 | 2944 | 0.130 |
Why?
|
| Amino Acid Substitution | 2 | 2009 | 644 | 0.130 |
Why?
|
| Anticholesteremic Agents | 1 | 1998 | 256 | 0.130 |
Why?
|
| Protein Structure, Tertiary | 2 | 2009 | 1487 | 0.120 |
Why?
|
| Caspase 3 | 3 | 2000 | 471 | 0.120 |
Why?
|
| Cell Line, Tumor | 5 | 2016 | 14551 | 0.120 |
Why?
|
| Aging | 2 | 2021 | 1582 | 0.120 |
Why?
|
| Nitriles | 4 | 2008 | 906 | 0.120 |
Why?
|
| Brain Mapping | 1 | 2018 | 644 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2018 | 1362 | 0.120 |
Why?
|
| Histone Deacetylases | 1 | 2016 | 365 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2016 | 7226 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2016 | 8873 | 0.110 |
Why?
|
| Gene Silencing | 1 | 2016 | 837 | 0.110 |
Why?
|
| Obesity | 2 | 2021 | 2884 | 0.110 |
Why?
|
| Indoles | 1 | 2018 | 1009 | 0.110 |
Why?
|
| Enzyme Activation | 4 | 2001 | 1764 | 0.110 |
Why?
|
| Chromones | 1 | 2012 | 120 | 0.110 |
Why?
|
| Body Weight | 3 | 2023 | 1293 | 0.110 |
Why?
|
| bcl-Associated Death Protein | 2 | 2002 | 26 | 0.110 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2012 | 167 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 4053 | 0.100 |
Why?
|
| Transcriptional Activation | 2 | 2008 | 1070 | 0.100 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2016 | 612 | 0.100 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2003 | 176 | 0.100 |
Why?
|
| Androstadienes | 1 | 2012 | 165 | 0.100 |
Why?
|
| Protein Isoforms | 2 | 2012 | 842 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2011 | 1648 | 0.100 |
Why?
|
| Morpholines | 1 | 2012 | 289 | 0.100 |
Why?
|
| Animals | 13 | 2016 | 59536 | 0.090 |
Why?
|
| Adipocytes | 1 | 2012 | 305 | 0.090 |
Why?
|
| Caspase 2 | 2 | 2000 | 39 | 0.090 |
Why?
|
| Mitochondria | 3 | 2002 | 1282 | 0.090 |
Why?
|
| Cytochrome c Group | 2 | 2000 | 71 | 0.090 |
Why?
|
| Adipokines | 1 | 2010 | 96 | 0.090 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2000 | 448 | 0.090 |
Why?
|
| Microscopy | 1 | 2011 | 182 | 0.090 |
Why?
|
| Genetic Vectors | 3 | 2011 | 1694 | 0.090 |
Why?
|
| Genes, Reporter | 3 | 2011 | 798 | 0.090 |
Why?
|
| Neoplasms | 4 | 2023 | 15193 | 0.090 |
Why?
|
| Poly(ADP-ribose) Polymerases | 3 | 2001 | 324 | 0.090 |
Why?
|
| Anorexia | 1 | 2010 | 143 | 0.080 |
Why?
|
| DNA Fragmentation | 2 | 2000 | 198 | 0.080 |
Why?
|
| Mutant Proteins | 1 | 2009 | 234 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2012 | 629 | 0.080 |
Why?
|
| Islets of Langerhans | 1 | 2009 | 229 | 0.080 |
Why?
|
| Cell Line | 3 | 2011 | 5114 | 0.080 |
Why?
|
| Mice, Nude | 3 | 2004 | 4307 | 0.080 |
Why?
|
| Protein Transport | 1 | 2009 | 734 | 0.080 |
Why?
|
| Ligands | 2 | 2008 | 995 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 3821 | 0.080 |
Why?
|
| Bone Density | 2 | 2021 | 476 | 0.070 |
Why?
|
| Lipoproteins, LDL | 1 | 2007 | 163 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2005 | 259 | 0.070 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2007 | 223 | 0.070 |
Why?
|
| HIV Infections | 1 | 2019 | 2134 | 0.070 |
Why?
|
| Fibroblasts | 2 | 2009 | 1682 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2005 | 280 | 0.070 |
Why?
|
| DNA, Complementary | 2 | 2000 | 869 | 0.070 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2005 | 347 | 0.070 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2009 | 488 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 2 | 2003 | 3101 | 0.070 |
Why?
|
| Disease Progression | 2 | 2012 | 6682 | 0.070 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2006 | 323 | 0.070 |
Why?
|
| Prevalence | 2 | 2023 | 3260 | 0.070 |
Why?
|
| Aged | 10 | 2023 | 70117 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2004 | 639 | 0.060 |
Why?
|
| Activating Transcription Factor 1 | 1 | 2004 | 21 | 0.060 |
Why?
|
| DNA | 6 | 2023 | 2693 | 0.060 |
Why?
|
| Butyrates | 2 | 2008 | 57 | 0.060 |
Why?
|
| Estrogen Receptor alpha | 1 | 2009 | 701 | 0.060 |
Why?
|
| Mexican Americans | 1 | 2006 | 322 | 0.060 |
Why?
|
| Co-Repressor Proteins | 1 | 2004 | 122 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2023 | 2803 | 0.060 |
Why?
|
| RNA, Ribosomal, 18S | 1 | 2023 | 25 | 0.060 |
Why?
|
| Gulf War | 1 | 2023 | 8 | 0.060 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2004 | 190 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 769 | 0.060 |
Why?
|
| Quality of Life | 3 | 2023 | 4532 | 0.060 |
Why?
|
| Antigens | 1 | 2004 | 292 | 0.060 |
Why?
|
| Carcinoma | 1 | 1995 | 2578 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 891 | 0.060 |
Why?
|
| Appetite | 3 | 2010 | 73 | 0.060 |
Why?
|
| Antibody Formation | 1 | 2004 | 383 | 0.060 |
Why?
|
| Transcription Factors | 3 | 2004 | 5270 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 7222 | 0.060 |
Why?
|
| Trinucleotide Repeats | 1 | 2003 | 106 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 660 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2008 | 2084 | 0.050 |
Why?
|
| COS Cells | 1 | 2003 | 377 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2021 | 6100 | 0.050 |
Why?
|
| Insulin | 3 | 2018 | 1454 | 0.050 |
Why?
|
| Immunization | 1 | 2004 | 397 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2003 | 611 | 0.050 |
Why?
|
| Plasmids | 1 | 2004 | 837 | 0.050 |
Why?
|
| Phenotype | 2 | 2012 | 6295 | 0.050 |
Why?
|
| Europe | 1 | 2023 | 649 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 2 | 1999 | 110 | 0.050 |
Why?
|
| Neuregulin-1 | 1 | 2001 | 83 | 0.050 |
Why?
|
| Middle Aged | 10 | 2023 | 86204 | 0.050 |
Why?
|
| Ghrelin | 3 | 2006 | 79 | 0.050 |
Why?
|
| Vitamin D | 1 | 2003 | 261 | 0.050 |
Why?
|
| Spain | 1 | 2021 | 113 | 0.050 |
Why?
|
| Genistein | 1 | 2001 | 73 | 0.050 |
Why?
|
| Sexual Maturation | 1 | 2001 | 65 | 0.050 |
Why?
|
| Urogenital System | 1 | 2001 | 59 | 0.050 |
Why?
|
| Tretinoin | 1 | 2003 | 623 | 0.050 |
Why?
|
| Subcellular Fractions | 1 | 2001 | 201 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2001 | 196 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2004 | 690 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 4320 | 0.050 |
Why?
|
| RNA, Messenger | 4 | 2004 | 6150 | 0.050 |
Why?
|
| Lac Operon | 1 | 2000 | 122 | 0.050 |
Why?
|
| Disorders of Sex Development | 1 | 2001 | 88 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2004 | 848 | 0.050 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2000 | 58 | 0.050 |
Why?
|
| Neuroimaging | 1 | 2023 | 403 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2021 | 118 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2003 | 2927 | 0.050 |
Why?
|
| Intracellular Membranes | 1 | 2000 | 108 | 0.050 |
Why?
|
| Weight Reduction Programs | 1 | 2021 | 78 | 0.050 |
Why?
|
| Point Mutation | 1 | 2003 | 769 | 0.050 |
Why?
|
| Mice | 6 | 2012 | 34495 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 2001 | 396 | 0.040 |
Why?
|
| Cell Division | 3 | 2004 | 2489 | 0.040 |
Why?
|
| Catalysis | 1 | 2000 | 250 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2023 | 1217 | 0.040 |
Why?
|
| Cytosol | 1 | 2000 | 238 | 0.040 |
Why?
|
| Models, Animal | 1 | 2002 | 664 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 1998 | 7789 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2003 | 993 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2001 | 614 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2003 | 1064 | 0.040 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2019 | 84 | 0.040 |
Why?
|
| Forecasting | 1 | 2002 | 694 | 0.040 |
Why?
|
| DNA Mutational Analysis | 2 | 2003 | 2283 | 0.040 |
Why?
|
| Caspase Inhibitors | 1 | 1999 | 95 | 0.040 |
Why?
|
| Steroids | 1 | 2001 | 356 | 0.040 |
Why?
|
| Testis | 2 | 2001 | 717 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2021 | 205 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2001 | 2074 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2019 | 239 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2000 | 886 | 0.040 |
Why?
|
| Cryptorchidism | 1 | 1998 | 40 | 0.040 |
Why?
|
| Biological Transport | 1 | 2000 | 597 | 0.040 |
Why?
|
| Homeostasis | 2 | 2018 | 950 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2012 | 5637 | 0.040 |
Why?
|
| Necrosis | 1 | 2000 | 580 | 0.040 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1998 | 82 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 6009 | 0.040 |
Why?
|
| Multienzyme Complexes | 1 | 1999 | 213 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2004 | 1555 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2021 | 288 | 0.040 |
Why?
|
| Anthropometry | 1 | 2018 | 269 | 0.040 |
Why?
|
| Skin Diseases | 1 | 2001 | 349 | 0.040 |
Why?
|
| Coinfection | 1 | 2019 | 189 | 0.040 |
Why?
|
| Heat-Shock Proteins | 1 | 1999 | 311 | 0.040 |
Why?
|
| Frailty | 1 | 2019 | 113 | 0.040 |
Why?
|
| Insulin Resistance | 3 | 2010 | 731 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 4314 | 0.040 |
Why?
|
| Life Style | 1 | 2021 | 612 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2000 | 621 | 0.040 |
Why?
|
| Female | 10 | 2023 | 141928 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 460 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2021 | 558 | 0.040 |
Why?
|
| Fractures, Bone | 1 | 2019 | 291 | 0.040 |
Why?
|
| Androgen-Binding Protein | 2 | 1995 | 39 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 3203 | 0.040 |
Why?
|
| Leptin | 2 | 2010 | 295 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 401 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 4821 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2004 | 4804 | 0.030 |
Why?
|
| Connectome | 1 | 2018 | 112 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2018 | 397 | 0.030 |
Why?
|
| Age of Onset | 1 | 2018 | 827 | 0.030 |
Why?
|
| Sex Differentiation | 1 | 1996 | 41 | 0.030 |
Why?
|
| Epithelium | 1 | 1998 | 720 | 0.030 |
Why?
|
| Registries | 1 | 2023 | 2170 | 0.030 |
Why?
|
| Androstenedione | 1 | 1995 | 18 | 0.030 |
Why?
|
| Hypospadias | 1 | 1996 | 77 | 0.030 |
Why?
|
| Rats | 2 | 2002 | 6086 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2021 | 2588 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 1995 | 60 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 605 | 0.030 |
Why?
|
| Somatomedins | 1 | 1995 | 75 | 0.030 |
Why?
|
| Serum Albumin | 2 | 2006 | 257 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 550 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2002 | 1818 | 0.030 |
Why?
|
| Critical Care | 1 | 2021 | 770 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 471 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 1995 | 260 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 1544 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2021 | 941 | 0.030 |
Why?
|
| Hepatitis C | 1 | 2019 | 524 | 0.030 |
Why?
|
| Pyridones | 1 | 2016 | 348 | 0.030 |
Why?
|
| Stromal Cells | 1 | 1997 | 825 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 1183 | 0.030 |
Why?
|
| Risk Factors | 2 | 2021 | 17523 | 0.030 |
Why?
|
| 3T3-L1 Cells | 1 | 2012 | 77 | 0.030 |
Why?
|
| Support Vector Machine | 1 | 2012 | 44 | 0.030 |
Why?
|
| Aromatase Inhibitors | 1 | 1995 | 305 | 0.030 |
Why?
|
| United States | 2 | 2021 | 15433 | 0.030 |
Why?
|
| Genome, Human | 1 | 2021 | 1869 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1992 | 105 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 2352 | 0.030 |
Why?
|
| Oxidoreductases | 1 | 1992 | 171 | 0.030 |
Why?
|
| Blotting, Western | 1 | 1998 | 3536 | 0.030 |
Why?
|
| Proteins | 1 | 2000 | 1963 | 0.030 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2012 | 192 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 1998 | 1960 | 0.020 |
Why?
|
| Automation, Laboratory | 1 | 2011 | 27 | 0.020 |
Why?
|
| Luminescent Proteins | 2 | 2004 | 289 | 0.020 |
Why?
|
| Interleukin-6 | 2 | 2006 | 1038 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2003 | 5178 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2012 | 931 | 0.020 |
Why?
|
| Resistin | 1 | 2010 | 39 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2006 | 1538 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 4971 | 0.020 |
Why?
|
| Adult | 4 | 2023 | 77950 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2000 | 5112 | 0.020 |
Why?
|
| Streptozocin | 1 | 2009 | 75 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 8865 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1998 | 2359 | 0.020 |
Why?
|
| Adiponectin | 1 | 2010 | 163 | 0.020 |
Why?
|
| Testosterone Congeners | 1 | 2008 | 26 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 4549 | 0.020 |
Why?
|
| Benzopyrans | 1 | 2008 | 41 | 0.020 |
Why?
|
| Exons | 1 | 1992 | 1328 | 0.020 |
Why?
|
| Oxazoles | 1 | 2008 | 60 | 0.020 |
Why?
|
| Estrogen Receptor beta | 1 | 2009 | 155 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 1 | 2 | 1999 | 236 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2009 | 276 | 0.020 |
Why?
|
| Binding Sites | 1 | 1992 | 2171 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 1053 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 598 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 5047 | 0.020 |
Why?
|
| Insulin-Secreting Cells | 1 | 2009 | 154 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2009 | 224 | 0.020 |
Why?
|
| Histone Acetyltransferases | 2 | 1999 | 411 | 0.020 |
Why?
|
| Cytoplasm | 2 | 1999 | 652 | 0.020 |
Why?
|
| X Chromosome | 2 | 1999 | 339 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2006 | 191 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 1085 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2006 | 59 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2006 | 40 | 0.020 |
Why?
|
| Child | 3 | 2023 | 29154 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2019 | 37905 | 0.020 |
Why?
|
| Finasteride | 2 | 1997 | 31 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 2006 | 165 | 0.020 |
Why?
|
| Cattle | 1 | 2007 | 783 | 0.020 |
Why?
|
| Estradiol | 1 | 2009 | 748 | 0.020 |
Why?
|
| Pancreas | 1 | 2009 | 718 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 1099 | 0.020 |
Why?
|
| Peptide YY | 1 | 2005 | 21 | 0.020 |
Why?
|
| Thymidine | 1 | 2005 | 155 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2000 | 13658 | 0.020 |
Why?
|
| Injections, Intradermal | 1 | 2004 | 58 | 0.020 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2005 | 160 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2004 | 394 | 0.020 |
Why?
|
| Adolescent | 2 | 2018 | 31252 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2016 | 3518 | 0.010 |
Why?
|
| Aorta | 1 | 2007 | 692 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2004 | 521 | 0.010 |
Why?
|
| Luciferases | 1 | 2004 | 445 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2004 | 32848 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 4298 | 0.010 |
Why?
|
| Health Promotion | 1 | 2006 | 502 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 2307 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2009 | 2086 | 0.010 |
Why?
|
| Protein Kinase C-alpha | 1 | 2001 | 66 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 7702 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2012 | 4078 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 29902 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 1533 | 0.010 |
Why?
|
| Genes, erbB-2 | 1 | 2001 | 229 | 0.010 |
Why?
|
| Prognosis | 1 | 1998 | 21713 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 21445 | 0.010 |
Why?
|
| NEDD8 Protein | 1 | 1999 | 22 | 0.010 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 1999 | 29 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2009 | 5710 | 0.010 |
Why?
|
| Response Elements | 1 | 1999 | 193 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2004 | 2314 | 0.010 |
Why?
|
| Gene Expression | 1 | 2007 | 3570 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 1998 | 10331 | 0.010 |
Why?
|
| Ubiquitins | 1 | 1999 | 86 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2006 | 2203 | 0.010 |
Why?
|
| Cysteine | 1 | 1999 | 214 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2004 | 1016 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 2450 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2001 | 1313 | 0.010 |
Why?
|
| Skin | 1 | 2004 | 1259 | 0.010 |
Why?
|
| Tyrosine | 1 | 1999 | 498 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 7548 | 0.010 |
Why?
|
| Receptors, Steroid | 1 | 1999 | 286 | 0.010 |
Why?
|
| Mevalonic Acid | 1 | 1997 | 34 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2001 | 15694 | 0.010 |
Why?
|
| Cell Movement | 1 | 2005 | 2466 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 1999 | 571 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 1999 | 694 | 0.010 |
Why?
|
| Diterpenes | 1 | 1997 | 111 | 0.010 |
Why?
|
| Mitosis | 1 | 1999 | 615 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 1999 | 589 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1999 | 1471 | 0.010 |
Why?
|
| Kidney | 1 | 2005 | 2146 | 0.010 |
Why?
|
| Y Chromosome | 1 | 1996 | 77 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 1998 | 417 | 0.010 |
Why?
|
| Secretoglobins | 1 | 1995 | 6 | 0.010 |
Why?
|
| Prostatein | 1 | 1995 | 6 | 0.010 |
Why?
|
| Uteroglobin | 1 | 1995 | 54 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1995 | 300 | 0.010 |
Why?
|
| Molecular Biology | 1 | 1996 | 176 | 0.010 |
Why?
|
| Kinetics | 1 | 1997 | 2049 | 0.010 |
Why?
|
| Cholesterol | 1 | 1997 | 658 | 0.010 |
Why?
|
| Organ Size | 1 | 1995 | 690 | 0.010 |
Why?
|
| Models, Biological | 1 | 2001 | 3254 | 0.010 |
Why?
|
| Time Factors | 1 | 2006 | 12926 | 0.010 |
Why?
|
| Ovary | 1 | 1996 | 668 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 14889 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1997 | 3033 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 2063 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 1997 | 849 | 0.010 |
Why?
|